• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Control Release . Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates

tetano

Editor, Senior Moderator
J Control Release


. 2025 Jun 5:113936.
doi: 10.1016/j.jconrel.2025.113936. Online ahead of print. Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates

Erik S Pena[SUP] 1 [/SUP], Luis Ontiveros-Padilla[SUP] 2 [/SUP], Nicole R Lukesh[SUP] 2 [/SUP], Grace L Williamson[SUP] 2 [/SUP], Connor T Murphy[SUP] 2 [/SUP], Dylan A Hendy[SUP] 2 [/SUP], John A Roque 3rd[SUP] 2 [/SUP], Michael A Carlock[SUP] 3 [/SUP], Ted M Ross[SUP] 4 [/SUP], Kristy M Ainslie[SUP] 5 [/SUP], Eric M Bachelder[SUP] 2 [/SUP]



Affiliations
Abstract

The influenza virus continues to impose a significant yearly burden on society due to the variable efficacy of seasonal vaccines. Further strains like H5N1, that are not included in the seasonal influenza vaccine, may spill over from animal reservoirs and more significantly impact human health. A broadly acting subunit vaccine can offer protection across multiple strains but would have low immunogenicity without an adjuvant, which are currently limited and require delivery systems to mitigate side effects. Further, antigen delivery can be enhanced with carrier systems to provide dose sparing, and thermostability. This study explores acetalated dextran microparticles (Ace-DEX MPs) encapsulating cGAMP and computational optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins, to form a multivalent influenza vaccine. Previous research has shown that Ace-DEX cGAMP MPs with varying degradation kinetics can modulate the immune response. Here, we investigate the effects of mixing MPs with different degradation rates to optimize the immune response. Mice vaccinated with slower-degrading cGAMP MPs exhibited higher IgG2a titers and IL-2 producing splenocytes, while those vaccinated with a mix of fast and slow-degrading cGAMP MPs had the highest IFN-γ producing splenocytes. The protection afforded in mice was also shown in ferrets with a H1, H3 and H5 trivalent COBRA formulation adjuvanted by slow degrading cGAMP MPs. Furthermore, using Ace-DEX MPs encapsulating two broadly reactive COBRA H1 and H3 immunogens in particles with fast and slow degradation rates, co-delivered with cGAMP MPs, resulted in less single antigen dominance when the more dominant antigen was encapsulated in the slowest degrading MP. This work underscores the utility of Ace-DEX MPs as a vaccine delivery platform and the impact of MP degradation kinetics on vaccine efficacy.

Keywords: Acetalated dextran; Antibody response; Cellular response; Flu vaccine; Nanoparticles; Tunable release.

 
Back
Top Bottom